Sera Prognostics Q2 Revenue Rises on Medicaid Mandate and New Partnerships
SERA sits 29% above its 52-week low of $1.56.
Summary
Sera Prognostics reported Q2 revenue growth driven by the Illinois Medicaid mandate and a fourth partnership program, expanding PreTRM test adoption. Net loss widened to $0.18 per share as operating expenses increased for commercial execution. The company ended the quarter with $80.3 million in cash, funding operations through 2029 milestones. CE marking submission in Europe is expected in Q4 2026, a key regulatory step for international expansion.
At the time of this announcement, SERA was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.1M. The 52-week trading range was $1.56 to $3.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.